Expanding what's possible in AAV gene therapy today.
Affinia Therapeutics pioneers rationally designed AAV gene therapies for rare and prevalent diseases, focusing on heart and nervous system disorders. Using AI and structural modeling, their ART platform creates novel capsids for improved tissue targeting, safety, and efficacy. Their lead program AFTX-201 targets BAG3-associated dilated cardiomyopathy.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountOct 2025
May 2021
Mar 2020
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
